Cases & Deals

Celgene licenses patents to Teva for marketing generic version of Focalin capsules and tablets

Clients Celgene Corporation

Jones Day represented Celgene in its licensing to Teva Pharmaceuticals of patents related to the manufacture of Celgene's Focalin XR capsules and Focalin IR tablets. The licensing was part of a settlement that concluded Hatch-Waxman patent litigation initiated by Celgene and Novartis Pharmaceuticals in response to Teva's filing of an abbreviated new drug application with the US FDA to market a generic equivalent of such drugs.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.